Methotrexate therapy in childhood systemic lupus erythematosus Article

•  
• Overview
•  
• Research
•  
• Identity
•  
• Additional Document Info
•  
• View All
•  

Overview

abstract

• We evaluated the therapeutic potential of methotrexate (MTX) in patients with systemic lupus erythematosus (SLE). Their serious disease ruled out further treatment with prednisone or prednisone plus cyclophosphamide. Low dose oral MTX (5-10 mg/week) was added to the therapy (prednisone or prednisone plus cyclophosphamide) of 10 selected patients with SLE. Eight of them showed marked improvement and we were able to taper prednisone and completely discontinue cyclophosphamide therapy. Our results suggest that the use of oral MTX in low, weekly doses can be useful as adjunctive therapy for selected cases of childhood SLE.

authors

• Abud Mendoza Carlos
• González Amaro Roberto Fidencio
• Sturbaum A.K.
• Vazquez-Compean R.

publication date

• 1993-01-01

published in

• Journal of Rheumatology  Journal

Research

keywords

• childhood; methotrexate; systemic lupus erythematosus cyclophosphamide; methotrexate; prednisone; adolescent; article; clinical article; female; gastrointestinal disease; human; male; oral drug administration; priority journal; school child; systemic lupus erythematosus; Administration, Oral; Adolescent; Child; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Combinations; Human; Lupus Erythematosus, Systemic; Methotrexate; Prednisone; Treatment Outcome

Identity

PubMed ID

• 8496874

Additional Document Info

start page

• 731

end page

• 733

volume

• 20

issue

• 4